Provided by Tiger Trade Technology Pte. Ltd.

Candel Therapeutics, Inc.

10.44
-0.4400-4.04%
Post-market: 10.550.1100+1.05%18:49 EDT
Volume:1.27M
Turnover:13.48M
Market Cap:798.85M
PE:-7.26
High:11.25
Open:11.02
Low:10.37
Close:10.88
52wk High:14.00
52wk Low:4.35
Shares:76.52M
Float Shares:60.06M
Volume Ratio:1.35
T/O Rate:2.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4390
EPS(LYR):-0.7210
ROE:-81.84%
ROA:-28.64%
PB:6.33
PE(LYR):-14.48

Loading ...

Candel Therapeutics Reports Phase 3 Prostate Cancer Biomarker Data Showing Sustained Immune Remodeling After Aglatimagene Treatment

Reuters
·
Yesterday

Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at Astro 2026

THOMSON REUTERS
·
Yesterday

Candel Therapeutics Shares Rise After BofA Upgrade

MT Newswires Live
·
Sep 22

H.C. Wainwright Remains a Buy on Candel Therapeutics (CADL)

TIPRANKS
·
Sep 22

BofA Upgrades Candel Therapeutics to Buy From Neutral, Price Target is $18

MT Newswires Live
·
Sep 21

Candel Therapeutics upgraded to Buy from Neutral at BofA

TIPRANKS
·
Sep 21

Candel Therapeutics CEO Paul Peter Tak Disposes of Common Shares Worth $3,164,815.85

Reuters
·
Sep 12

Candel Therapeutics Director Martine Zimmermann Files Initial Beneficial Ownership Statement

Reuters
·
Sep 11

Candel Therapeutics Adds Independent Director to Board

TIPRANKS
·
Sep 10

Candel Therapeutics Appoints Martine Zimmermann, Pharmd, to Its Board of Directors

THOMSON REUTERS
·
Sep 10

Press Release: Candel Therapeutics Appoints Martine Zimmermann, PharmD, to Its Board of Directors

Dow Jones
·
Sep 10

Candel Therapeutics Highlights Progress of Lead Oncology Candidate

TIPRANKS
·
Sep 10

Candel Therapeutics Grants 31,400 Inducement Stock Options at $13.07 Per Share

Reuters
·
Sep 02

Candel Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Sep 02

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Sep 02

Candel Therapeutics CEO to Speak at Citi Biopharma Back to School Conference Fireside Chat

Reuters
·
Aug 26

Candel Therapeutics to Present at September Investor Conferences

GlobeNewswire
·
Aug 26

Has Candel Therapeutics (CADL) Run Too Far Ahead On Widening Losses?

Simply Wall St.
·
Aug 24

Candel Therapeutics CTO Seshu Tyagarajan Sells 7,000 Shares for $84,000

Reuters
·
Aug 20

Candel Therapeutics is Maintained at Neutral by B of a Securities

Dow Jones
·
Aug 15